Top 10 Venture Round Investors in Cancer Therapeutics

by | Jan 22, 2019

Celgene’s recent acquisition offer by Bristol-Myers Squibb has raised attention to its prolific dealmaking history. We covered this in a recent article in Endpoints News. Celgene was also very active in venture round participation. Here’s a quick look at how Celgene ranked in its investment activity since 2010 in venture rounds at cancer therapeutics companies.

Run your own analysis with your DealForma access.

Schedule a Demo to See it in Action

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.

14,216

Deal Profiles

7,283

Funding Rounds

16,812

Company Profiles

5,183

Product Brands

118K+

Clinical Trials

2,579

Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

DealForma is the biopharma database providing you comprehensive information and analyst support hours to help you be more confident using quality data in your business development research.

 

Company

About Us

Blog

Contact Us

Product

Support

Pricing

Connect

Made in San Mateo, CA and around the world    support@dealforma.com   (650) 353-9363  Terms  Privacy

Copyright © 2019 DealForma, LLC.

Share This